Buys | $642,845 | 8 | 100 |
Sells | $0 | 0 | 0 |
TRAVERSA SERGIO | Chief Executive Officer | 3 | $395,115 | 0 | $0 | $395,115 |
Shenouda Maged | Chief Financial Officer | 3 | $149,701 | 0 | $0 | $149,701 |
Kelly Paul Edward | director | 1 | $64,750 | 0 | $0 | $64,750 |
CASAMENTO CHARLES J | director | 1 | $33,280 | 0 | $0 | $33,280 |
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
Over the last 12 months, insiders at Relmada Therapeutics, Inc. have bought $642,845 and sold $0 worth of Relmada Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Relmada Therapeutics, Inc. have bought $484,608 and sold $1.99M worth of stock each year.
Highest buying activity among insiders over the last 12 months: TRAVERSA SERGIO (Chief Executive Officer) — $395,115. Shenouda Maged (Chief Financial Officer) — $149,701. Kelly Paul Edward (director) — $64,750.
The last purchase of 51,407 shares for transaction amount of $153,707 was made by TRAVERSA SERGIO (Chief Executive Officer) on 2024‑09‑11.
2024-09-11 | TRAVERSA SERGIO | Chief Executive Officer | 51,407 0.1813% | $2.99 | $153,707 | -40.39% | ||
2024-09-11 | Shenouda Maged | Chief Financial Officer | 24,120 0.0839% | $2.95 | $71,154 | -40.39% | ||
2024-09-10 | TRAVERSA SERGIO | Chief Executive Officer | 33,014 0.1071% | $2.75 | $90,789 | -35.93% | ||
2024-09-10 | Shenouda Maged | Chief Financial Officer | 21,118 0.068% | $2.73 | $57,652 | -35.93% | ||
2024-09-09 | TRAVERSA SERGIO | Chief Executive Officer | 55,579 0.1789% | $2.71 | $150,619 | -35.33% | ||
2024-09-09 | Kelly Paul Edward | director | 25,000 0.0769% | $2.59 | $64,750 | -35.33% | ||
2024-09-09 | Shenouda Maged | Chief Financial Officer | 8,194 0.0248% | $2.55 | $20,895 | -35.33% | ||
2024-09-09 | CASAMENTO CHARLES J | director | 13,000 0.0395% | $2.56 | $33,280 | -35.33% | ||
2024-01-31 | TRAVERSA SERGIO | Chief Executive Officer | 27,460 0.0923% | $4.00 | $109,752 | -15.27% | ||
2024-01-31 | Ence Chuck | CA and CO | 13,670 0.0466% | $4.05 | $55,429 | -15.27% | ||
2024-01-31 | Shenouda Maged | Chief Financial Officer | 6,875 0.0235% | $4.06 | $27,943 | -15.27% | ||
2024-01-30 | TRAVERSA SERGIO | Chief Executive Officer | 40,999 0.1345% | $3.90 | $159,949 | -16.08% | ||
2024-01-30 | Shenouda Maged | Chief Financial Officer | 15,000 0.0491% | $3.89 | $58,323 | -16.08% | ||
2024-01-30 | Ence Chuck | CA and CO | 14,500 0.0471% | $3.87 | $56,053 | -16.08% | ||
2024-01-29 | TRAVERSA SERGIO | Chief Executive Officer | 31,541 0.1037% | $3.71 | $117,036 | -9.95% | ||
2024-01-29 | Shenouda Maged | Chief Financial Officer | 10,800 0.035% | $3.65 | $39,450 | -9.95% | ||
2024-01-29 | Ence Chuck | CA and CO | 10,800 0.0349% | $3.65 | $39,438 | -9.95% | ||
2023-05-23 | O'Gorman Cedric | Chief Medical Officer | 10,000 0.0338% | $3.18 | $31,800 | +0.32% | ||
2022-12-08 | TRAVERSA SERGIO | Chief Executive Officer | 55,250 0.1801% | $2.10 | $115,804 | +37.79% | ||
2022-06-30 | Sale | TRAVERSA SERGIO | Chief Executive Officer | 4,068 0.0131% | $18.32 | $74,526 | -73.16% |
TRAVERSA SERGIO | Chief Executive Officer | 384024 1.2727% | $113,939.92 | 9 | 14 | <0.0001% |
Kelly Paul Edward | director | 212295 0.7036% | $62,987.93 | 6 | 11 | +80.43% |
Shenouda Maged | Chief Financial Officer | 88335 0.2928% | $26,208.99 | 9 | 14 | <0.0001% |
CASAMENTO CHARLES J | director | 13000 0.0431% | $3,857.10 | 2 | 15 | |
SETH SANDESH | director | 123258 0.4085% | $36,570.65 | 2 | 0 |
$18,881,323 | 88 | -48.96% | $6.99M | |
$1,241,605 | 44 | -21.46% | $8.75M | |
$523,320 | 24 | 94.37% | $6.98M | |
$746,223 | 23 | -7.24% | $6.79M | |
$86,569,038 | 18 | -12.64% | $9.15M |
Increased Positions | 17 | +15.74% | 787,351 | +6.35% |
Decreased Positions | 48 | -44.44% | 5M | -38.44% |
New Positions | 7 | New | 164,940 | New |
Sold Out Positions | 28 | Sold Out | 3M | Sold Out |
Total Postitions | 77 | -28.7% | 8M | -32.08% |
Franklin Resources Inc | $387.00 | 3.95% | 1.3M | 0 | 0% | 2024-12-31 |
Vanguard Group Inc | $373.00 | 3.81% | 1.26M | 0 | 0% | 2024-12-31 |
Acadian Asset Management Llc | $365.00 | 3.72% | 1.23M | +41,476 | +3.5% | 2024-12-31 |
Blackrock, Inc. | $176.00 | 1.8% | 593,326 | +25,446 | +4.48% | 2024-12-31 |
Palo Alto Investors Lp | $147.00 | 1.5% | 495,146 | -237,254 | -32.39% | 2024-12-31 |
Geode Capital Management, Llc | $90.00 | 0.92% | 302,838 | -1,664 | -0.55% | 2024-12-31 |
Deutsche Bank Ag | $67.00 | 0.68% | 224,846 | 0 | 0% | 2024-12-31 |
Ubs Group Ag | $64.00 | 0.65% | 215,140 | +88,755 | +70.23% | 2024-12-31 |
Advisorshares Investments Llc | $62.00 | 0.64% | 210,068 | +141,540 | +206.54% | 2024-12-31 |
Bank Of America Corp /De/ | $61.00 | 0.63% | 206,657 | <1 | 0% | 2024-12-31 |